News|Articles|November 16, 2026

Roflumilast cream 0.05% eases itch, improves QOL in infants with AD

Fact checked by: Benjamin P. Saylor

Key Takeaways

  • In the open-label INTEGUMENT-INFANT trial, caregivers reported rapid itch relief and a drop in mean POEM scores from moderate (14.5) to mild (6.5) severity after 4 weeks of once-daily roflumilast cream 0.05% in infants aged 3 to <24 months.
  • No serious or severe adverse events occurred among 101 infants, and at least 97.9% showed no application-site irritation, though the 4-week, single-arm design limits conclusions about efficacy and long-term safety.
SHOW MORE

Caregivers reported itch, symptom, and QOL gains with roflumilast cream 0.05% in infants with AD; an FDA decision is due February 2027.

Caregivers of infants with mild to moderate atopic dermatitis (AD) reported improvements in itch, eczema symptoms, and quality of life over 4 weeks of once-daily roflumilast cream 0.05% (Zoryve; Arcutis Biotherapeutics), according to caregiver-reported outcomes from the phase 2 INTEGUMENT-INFANT trial presented at the American College of Allergy, Asthma & Immunology Annual Scientific Meeting.¹ The topical phosphodiesterase 4 (PDE4) inhibitor is under FDA review for infants aged 3 to 24 months, with a target action date of February 23, 2027.¹

"Today, there are very limited approved treatment options for infants, especially steroid-free options, leaving healthcare providers and caregivers with too few options," said Mark Boguniewicz, MD, professor in the Department of Pediatrics at National Jewish Health and the University of Colorado School of Medicine.¹

INTEGUMENT-INFANT itch outcomes with roflumilast cream 0.05%

INTEGUMENT-INFANT was an open-label, single-arm study that enrolled 101 infants aged 3 to less than 24 months with mild to moderate AD, who applied roflumilast cream 0.05% once daily for 4 weeks.¹,²

Caregiver-rated itch improved within minutes of the first application. At 10 minutes, 46.6% of infants (n = 88) had at least a 25% improvement on the Dynamic Pruritus Score, rising to 66.7% at 4 hours (n = 87).¹ Worst Scratch/Itch Numeric Rating Scale (WSI-NRS) success was achieved by 10.4% of infants at 24 hours and 72.7% at the last assessment (n = 77 for both).¹

POEM and quality-of-life results in infants with atopic dermatitis

Mean Patient-Oriented Eczema Measure (POEM) scores, which capture the weekly frequency of symptoms such as bleeding, cracking, weeping, itching, and sleep loss on a 0-to-28 scale, fell from 14.5 at baseline to 7.9 at week 2 (n = 100) and 6.5 at week 4 (n = 96), a shift from moderate to mild severity.¹ Caregivers also reported improvements on the Infants' Dermatitis Quality of Life Index and the Dermatitis Family Impact questionnaire, in domains including sleep and family relationships, although the company did not release numerical results for either measure.¹

Previously reported investigator-assessed data from the trial showed that 34.4% of infants who completed 4 weeks of treatment (n = 96) achieved Validated Investigator Global Assessment for AD (vIGA-AD) success, and 67.5% achieved IGA-Scalp success.²

Roflumilast cream safety and tolerability in infants

No serious adverse events or severe treatment-emergent adverse events were reported among the 101 infants, and at least 97.9% had no investigator-rated application-site irritation at any assessment.¹

Infant atopic dermatitis burden and the steroid-free treatment gap

AD affects an estimated 9.6 million children in the United States, and up to 60% of affected children develop symptoms in the first year of life.¹ Itch-related sleep disruption in infants, along with the emotional and financial strain of treatment on caregivers, contributes substantially to disease burden.¹

"These new caregiver-reported outcomes showing improvement in both symptoms and quality of life measures add to the growing body of clinical evidence supporting the potential of ZORYVE cream 0.05% to address a significant unmet need for infants with atopic dermatitis and their families," said Patrick Burnett, MD, PhD, FAAD, chief medical officer of Arcutis.¹

Roflumilast PDE4 inhibition and prior pediatric AD data

Roflumilast inhibits PDE4, an intracellular enzyme, reducing production of proinflammatory mediators in the skin.¹ The 0.05% cream is approved for mild to moderate AD in children aged 2 to 5 years, and the 0.15% cream for patients aged 6 years and older.¹ In the phase 3, double-blind INTEGUMENT-PED trial of children aged 2 to 5 years, 25.4% of the 437 children receiving roflumilast cream 0.05% achieved week-4 vIGA-AD success vs 10.7% of the 215 receiving vehicle, and 39.4% vs 20.6% achieved a 75% improvement in Eczema Area and Severity Index.³ Boguniewicz was a coauthor of that publication.³

References
1. Arcutis presents new caregiver-reported outcomes data supporting ZORYVE (roflumilast) cream 0.05% for mild to moderate atopic dermatitis in infants down to 3 months at the ACAAI Annual Scientific Meeting. News release. Arcutis Biotherapeutics; November 13, 2026. Accessed November 16, 2026. https://www.globenewswire.com/news-release/2026/11/13/3402608/0/en/arcutis-presents-new-caregiver-reported-outcomes-data-supporting-zoryve-roflumilast-cream-0-05-for-mild-to-moderate-atopic-dermatitis-in-infants-down-to-3-months-at-the-acaai-annua.html
2. Arcutis presents ZORYVE (roflumilast) data and real-world topical corticosteroid research at EADV and Fall Clinical. News release. Arcutis Biotherapeutics; October 9, 2026. Accessed November 16, 2026. https://www.globenewswire.com/news-release/2026/10/09/3378045/0/en/arcutis-presents-zoryve-roflumilast-data-and-real-world-topical-corticosteroid-research-at-eadv-and-fall-clinical.html
3. Eichenfield LF, Serrao R, Prajapati VH, et al. Efficacy and safety of once-daily roflumilast cream 0.05% in pediatric patients aged 2-5 years with mild-to-moderate atopic dermatitis (INTEGUMENT-PED): a phase 3 randomized controlled trial. Pediatr Dermatol. 2025;42(2):296-304. doi:10.1111/pde.15840

Related to this article